You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)等五間內地藥企獲允許免費仿製輝瑞新冠口服藥
日內瓦藥品專利池(MPP)宣佈,已與35家藥企簽署協議,允許其生產輝瑞新冠口服藥Paxlovid成分之一奈瑪特韋(nirmatrelvir)原料藥或製劑,當中包括上海迪賽諾、華海藥業(600521.SH)、普洛藥業(000739.SZ)、復星醫藥(02196.HK)(600196.SH)、九洲藥業(603456.SH)五家內地藥企。 MPP表示,35家藥企遍佈12個國家,包括孟加拉、巴西、中國、約旦、印度、以色列、墨西哥、巴基斯坦、塞爾維亞、多明尼加、南韓及越南。 於去年11月,MMP已與輝瑞簽署一項自願許可協議,允許其他仿製藥企生產奈瑪特韋。在新冠肺炎仍被世衛列爲國際關注的突發公共衛生事件情況下,輝瑞將不會從MPP許可持有人的奈瑪特韋銷售中收取授權使用費。(ta/w) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account